Background: Psoriasis is a chronic inflammatory skin disease affecting approximately 1-6% of population in the world. Aim of the work: To screen psoriatic patients for psoriatic arthritis [PsA] to improve optimal PsA management and outcome.
Background: Vitiligo is a common disease of the skin, affecting epidermis and hair follicles. Both genders are affected. The main pathogenic mechanism of the disease is the destruction or inhibition of the epidermal melanocytes which is manifested clinically by presence of variable sized areas of skin depigmentation that can affect any site of the body. Aim of the work: To estimate the prevalence and risk of metabolic syndrome in vitiligo patients. Patients and Methods: This is a case control study that was conducted on 90 patients with vitiligo recruited from outpatient clinic, dermatology department of Al Azhar University Hospital in Damietta, and 60 healthy controls. Full history was taken from all the subjects included in the study. The cases were also subjected to careful general examination and dermatological examination to determine the site and the type of the lesion and the presence of any dermatological diseases, laboratory investigations including HDL, TG and FBS were done. Results: In this study we found that 35.6% of cases have metabolic syndrome while 33.3% of healthy controls have metabolic syndrome. We also found that there is no relation between presence of metabolic syndrome and disease extent, progression or stage. Conclusion: Incidence of metabolic syndrome is slightly higher in cases with vitiligo as compared to the control group. Presence of metabolic syndrome is not associated with disease severity, extent or stage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.